Abstract
We describe the striking and unexpected evolution of 10 patients with de novo multiple myeloma treated with novel-agent based induction therapy, who displayed a dissociated evolution characterised by an apparent good response contrasting with the concomitant development of aggressive non-secreting plasmocytomas immediately before, or just after, autologous stem cell transplantation. Patients did not respond to salvage therapies. Eight of them died from progression less than 12 months after diagnosis. This unusual evolution in the era of novel agents warrants further scrutiny.
Copyright © 2012 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Boronic Acids / administration & dosage
-
Bortezomib
-
Combined Modality Therapy
-
Disease Progression
-
Female
-
Humans
-
Immunologic Factors / administration & dosage
-
Induction Chemotherapy
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / radiotherapy
-
Multiple Myeloma / surgery
-
Prognosis
-
Pyrazines / administration & dosage
-
Salvage Therapy / methods*
-
Stem Cell Transplantation
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Immunologic Factors
-
Pyrazines
-
Bortezomib